Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-03-15
2011-03-15
Bristol, Lynn (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S093210, C424S185100, C435S366000
Reexamination Certificate
active
07906620
ABSTRACT:
The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.
REFERENCES:
patent: 6329503 (2001-12-01), Afar et al.
patent: 6833438 (2004-12-01), Afar et al.
patent: 2003/0092037 (2003-05-01), Matsuzaki et al.
patent: 2003/0148410 (2003-08-01), Berger et al.
patent: 2004/0037840 (2004-02-01), Beier et al.
patent: 2005/0063975 (2005-03-01), Afar et al.
Sequence search alignment for SEQ ID No. 41 (pp. 1-3).
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252).
Schwartz et al, Proc Natl Acad Sci USA vol. 84:6408-6411 (1987).
Lin et al Biochemistry USA vol. 14:1559-1563 (1975).
Sequence search alignment for residues 31-426 of SEQ ID No. 58 (pp. 1-2).
Machlenkin (Can. Res. 65:6435-6442 (2005)).
Machlenkin (Can. Immunol. Immunother.56:217-226 (2007).
Bar-Haim (Br. J. Can. 91:398-407 (2004).
Carmon (Int. J. Can. 85:391-397 (2000)).
Carmon (J. Clin. Invest. 110:453-462 (2002).
Stepensky (Clin. Exp. Immunol. 143:139-149 (2005).
Tirosh et al. Brit. J. Can. 97:1655-1663 (2007).
Lesterhuis et al. (Critical Reviews in Oncology/Hematology 66:118-134 (2008).
Trojan et al. (Lung Can. 36(2):151-158 (May 2002)).
Abrams et al. (Cell. Immunol. 182:137-1515 (1997)).
Tsang et al. (Can. Res. 61:7568-7576 (Oct. 15, 2001)).
Smith et al. (Nature Biotechnology 15:1222-1223 (1997)).
Brenner (Trends in Genetics 15:132-133 (1999)).
Sequence search alignment for residues 31-426 of SEQ ID No. 58 (pp. 1-2), (Jul. 10, 2007).
Sequence search alignment for SEQ ID No. 41 (pp. 1-3), (Apr. 12, 2007).
Schirle et al. (J. Immunol. Methods. 2001; 257: 1-16).
Anderson et al. (Tissue Antigens. Jun. 2000; 55 (6): 519-531).
Feltkamp et al. (Mol. Immunol. Dec. 1994; 31 (18): 1391-1401).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138).
Behr, Thomas M., “Radioimmunotherapy of Small-Volume Disease of Metastatic Colorectal Cancer: Results of a Phase II Trial with the Iodine-131-Labeled Humanized Anti-Carcinoembryonic Antigen Antibody hMN-14”, Cancer (2002), vol. 94, No. 4, pp. 1373-1381.
Chames, Patrick, “Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library”, PNAS (2000) 97:14, pp. 7969-7974.
Fishman, Pnina et al., “Autoantibodies to Tyrosinase: The Bridge between Melanoma and Vitiligo”, Cancer (1997), Vo. 79, No. 8, pp. 1461-1464.
Govorko, Dimitri et al., “Single-chain antibody against the common epitope of mutant p53: isolation and intracytosolic expression in mammalian cells”, Journal of Immunological Methods (2001), vol. 258, pp. 169-181.
Huang, Sharon K.S., “Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients”, (1998), vol. III, No. 4, The Journal of Investigative Dermatology, Inc., pp. 662-667.
Jager, Elke et al., “Humoral Immune Responses of Cancer Patients Against Cancer-Testis” Antigen NY-ESO-1: Correlation with Clinical Events, (1999) 84, Int. J. Cancer (Pred. Oncol.), pp. 506-510.
Lev, A. et al., “Isolation and Characterization of Human Recombinant Antibodies Endowed with the Antigen-specific, Major Histocompatibility Complex-restricted Specificity of T Cells Directed toward the Widely Expressed Tumor T-cell Epitopes of the Telomerase Catalytic Subunit”, (2002), Cancer Research, vol. 62, pp. 3184-3194.
Moase, E.H. et al., “Anti-MUC-1 Immunoliposomal doxorubicin in the treatment of murine models of metasttic breast cancer”, (2001), Biochimica et Biohysica Acta 1510, pp. 43-55.
Niethammer, Andreas G. et al., “An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice”, (2002), Vaccine 20, pp. 421-429.
Okamoto, Tetsuro et al., “Anti-Tyrosinase-Related Protein-2 Immune Response in Vitiligo patients and Melanoma Patients Receiving Active-Specific Immunotherapy”, (1998), The Journal of Investigative Dermatology, Inc., pp. 1034-1039.
Parker, Kenneth C., “Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains”, (1994), Journal of Immunology, pp. 163-175.
Reddish, Mark A., “Anti-MUC1 Class I Restricted CTLs in Metastatic Breast Cancer Patients Immunized with a Synthetic Muc1 Peptide”, (1998), vol. 76, Int. J. Cancer, pp. 817-823.
Ullenhag, Gustav J. et al., “Induction of IgG Subclass Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant Carcinoembryonic Antigen”, (2002), Cancer Research, vol. 62, pp. 1364-1369.
Yip, Yum L., “Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines”, (2002), vol. 50, Cancer Immunol Immunother, pp. 569-587.
Carmon, L et al “Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in Db-/-X β2 Microglobulin (β2m) Null Mice Transgenic for a Chimeric HLA-A2.1/Db-β2 Microglobulin Single Chain” Int. J. Cancer 85 (2000) pp. 391-397.
Carmon, L et al Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1Db-β2m transgenic mice: J. Clin. Invest. 110 (2002) pp. 453-462.
Celis, Esteban et al “Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes” Proc. Natl. Acad. Sci. vol. 91, (Mar. 1984) pp. 2105-2109.
Conroy, R.M. et al “Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adencarcinoma: Comparison of Intradermal versus Subcutaneous Administration” Clin Cancer Res. 5 (1999) pp. 2330-2337.
Deblandre, Gisele A. et al “Expression Cloning of an Interferon-inducible 17-kDa Membrane Protein Implicated in the Control of Cell Growth” The J. of Biological Chemistry vol. 270, No. 40 (Oct. 1995) pp. 23860-23866.
Firat, H et al “Comparative analysis of the CD8+T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice” Int. Immunol. 14 (2002) pp. 925-934.
Fong, Lawrence, et al “Induction of Tissue-Specific Autoimmune Prostatitis with Prostatic Acid Phosphatase Immunization: Implications for Immunotherapy of Prostate Cancer” The J. of Immunology (1997) pp. 3113-3117.
Hisamatsu, Tadakazu, et al “Interferon-inducible Gene Family 1-8U Expression in Colitis associated Colon Cancer and Severely Inflamed Mucosa in Ulcerative Colitis” J. Cancer Research 59 (1999) pp. 5927-5931.
Kawakami, Yutaka et al “Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression” The J. of Immunology (1995) pp. 3961-3968.
Lewin, Andrew R. et al “Molecular Analysis of a Human interferon-inducible gene family” J. Biochem. 199 (1991) pp. 417-423.
Machlenkin, A et al “Human CTL Epitopes Prostatic Acid Phosphates-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy” Cancer Res. 65 (2005) pp. 6435-6442.
Mandelboim, Ofer et al “Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides” Nature Medicine, vol. 1, No. 11, (No
Carmon Lior
Eisenbach Lea
Fridkin Matityahu
Machlenkin Arthur
Paz Adrian
Bristol Lynn
Browdy and Neimark PLLC
Yeda Research and Development Co. Ltd.
LandOfFree
Tumor associated antigen, peptides thereof, and use of same... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor associated antigen, peptides thereof, and use of same..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor associated antigen, peptides thereof, and use of same... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726474